TB-500, BPC-157, KPV & GHK-CU
A quad-peptide formulation combining TB-500 (a systemic cell migration peptide), BPC-157 (a localized tissue repair peptide), KPV (an anti-inflammatory tripeptide from alpha-MSH), and GHK-Cu (a copper peptide that activates collagen synthesis). Klow engages four distinct signaling pathways — tissue repair, cell migration, inflammatory modulation, and matrix remodeling — within a single formulation.
Klow is supplied as a lyophilized powder and reconstituted with bacteriostatic water. In research settings, it is administered via subcutaneous injection. The quad-peptide formulation reduces the complexity of multi-vial protocols by combining four individually studied compounds into a single reconstitution.
Klow represents one of the most comprehensive multi-peptide formulations in the research peptide space, combining tissue repair (BPC-157), systemic cell motility (TB-500), inflammatory modulation (KPV), and matrix remodeling (GHK-Cu) into a single protocol. Researchers are interested in whether four-pathway engagement produces effects beyond what individual peptides or smaller combinations achieve. It builds on the foundation established by the Wolverine Stack (BPC-157 + TB-500) and the Glow Blend (BPC-157 + TB-500 + GHK-Cu) by adding the KPV anti-inflammatory component.
For research purposes only. Not intended for consumption, clinical application, or diagnostic use.